Evidence map›Paper›PMID 41238841›Full record

ArticleMolecular psychiatry2026

The psychedelic phenethylamine 25C-NBF, a selective 5-HT2A agonist, shows psychoplastogenic properties and rapid antidepressant effects in male rodents.

Núria Nadal-Gratacós, Pol Puigseslloses, Laura Guzmán, Nicola Weiss, Eline Pottie, Clara Riera-Colomer, Virginie Lardeux, Nathalie Thiriet, Fu-Hua Wang, Liselott Källsten and 13 more

Abstract read
In one paragraph

Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Núria Nadal-GratacósDepartment of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, 08028, Barcelona, Spain.ORCID http://orcid.org/0000-0002-9791-249X
Pol PuigsesllosesDepartment of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, 08028, Barcelona, Spain.ORCID http://orcid.org/0000-0003-2542-972X
Laura GuzmánDepartment of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, 08028, Barcelona, Spain.
Nicola WeissDepartment of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, 08028, Barcelona, Spain.ORCID http://orcid.org/0000-0002-5487-6505
Eline PottieLaboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Campus Heymans, Ottergemsesteenweg 460, B-9000, Ghent, Belgium.ORCID http://orcid.org/0000-0002-9077-4055
Clara Riera-ColomerDepartment of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, 08028, Barcelona, Spain.
Virginie LardeuxLaboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, INSERM, U-1084, Poitiers, France.
Nathalie ThirietLaboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, INSERM, U-1084, Poitiers, France.ORCID http://orcid.org/0000-0002-0076-4946
Fu-Hua WangPronexus Analytical AB, Grindstuvägen 44, Bromma, 167 33, Stockholm, Sweden.
Liselott KällstenPronexus Analytical AB, Grindstuvägen 44, Bromma, 167 33, Stockholm, Sweden.
Irene Pérez-EstebanUnit of Research Psychobiology of Drug Dependence, Department of Psychobiology, Facultad de Psicología, Universitat de Valencia, Valencia, Spain.
Gabriel KetselaChemical Reactions for Innovative Solutions (CRISOL), IQS School of Engineering, Universitat Ramon Llull, 08017, Barcelona, Spain.
Joel MargallDepartment of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, 08028, Barcelona, Spain.
Xavier BerzosaChemical Reactions for Innovative Solutions (CRISOL), IQS School of Engineering, Universitat Ramon Llull, 08017, Barcelona, Spain.
David PubillDepartment of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, 08028, Barcelona, Spain.ORCID http://orcid.org/0000-0002-6627-4501
Marta Rodríguez-AriasUnit of Research Psychobiology of Drug Dependence, Department of Psychobiology, Facultad de Psicología, Universitat de Valencia, Valencia, Spain.
Miren EttchetoDepartment of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, 08028, Barcelona, Spain.
Jan KehrPronexus Analytical AB, Grindstuvägen 44, Bromma, 167 33, Stockholm, Sweden.
Christophe StoveLaboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Campus Heymans, Ottergemsesteenweg 460, B-9000, Ghent, Belgium.ORCID http://orcid.org/0000-0001-7126-348X
Marcello SolinasLaboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, INSERM, U-1084, Poitiers, France.ORCID http://orcid.org/0000-0002-0664-5964
Harald H SitteCenter for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0002-1339-7444
Elena EscubedoDepartment of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, 08028, Barcelona, Spain.ORCID http://orcid.org/0000-0002-5078-366X
Raul López-ArnauDepartment of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, 08028, Barcelona, Spain. raullopezarnau@ub.edu.ORCID http://orcid.org/0000-0001-8904-7398

Funding

Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) P33955 and P35589Bijzonder Onderzoeksfonds (Special Research Fund) BOF23/PDO/073Centre National pour la Recherche Scientifique et Technique (National Centre for Scientific and Technical Research) CPER 2015-2020 / FEDER 2014-2020European Commission (EC) 101045825
6 · The paper itself

Abstract

Psychedelics have garnered significant interest for their therapeutic potential in mental health conditions such as depression, anxiety, and post-traumatic stress disorder. While research has primarily focused on well-studied psychedelics, phenethylamine derivatives have also gathered interest for their potential therapeutic applications. Thus, this study aims to investigate the pharmacological profile, safety and therapeutic potential of novel N-(2-fluorobenzyl) phenethylamine analogs (NBFs) of the 2C-X series-25C-NBF, 25B-NBF, and 25I-NBF. NBFs displayed high affinity and selectivity for the 5-HT

Indexed as

Antidepressive AgentsHallucinogensPhenethylaminesSerotonin 5-HT2 Receptor AgonistsAnimalsBrain-Derived Neurotrophic FactorDepressionDopamineHumansMaleMiceMice, Inbred C57BLNucleus AccumbensRatsRats, Sprague-DawleyReceptor, Serotonin, 5-HT2AAntidepressive AgentsBrain-Derived Neurotrophic FactorDopamineHallucinogensPhenethylaminesReceptor, Serotonin, 5-HT2ASerotoninSerotonin 5-HT2 Receptor Agonists

Identifiers

PMID41238841
PMCPMC12999468

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.